louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06248346: Association Between Administration of Dexmedetomidine and Postoperative Mortality in Hospitals
Official title: Association Between Administration of Dexmedetomidine and Postoperative Mortality in Hospitals Among Inpatients Undergoing Surgeries Under General Anaesthesia Using Propofol
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: In-hospital Mortality
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
Collaborators: name: The Affiliated Hospital of Qingdao University
name: First Hospital of China Medical University
name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
name: Sir Run Run Shaw Hospital
First posted: 2024-02-08
Enrollment: 518043
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult patients (aged ≥18 years) admitted for surgical procedures under general anaesthesia with propofol at the five participating hospitals from January 1, 2014 to June 30, 2018.

Brief summary: The present multicentre retrospective cohort study aimed to investigate the association between intraoperative administration of dexmedetomidine and postoperative mortality in hospitals.

The investigators set out to test the hypothesis that perioperative dexmedetomidine use, as an adjunct to general anesthesia, diminishes postoperative mortality in hospitals across all categories of surgical patients.


Eligibility criteria: Inclusion Criteria:

* adult patients (aged ≥18 years)
* undergo general anaesthesia with propofol
* from January 1, 2014 to June 30, 2018

Exclusion Criteria:

* patients undergoing intervention procedures under monitored anaesthesia care (MAC)
* patients undergoing minor procedures under local or regional anaesthesia

Primary outcomes:
measure: in-hospital all-cause mortality
timeFrame: from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 1 year
Secondary outcomes:
measure: length of postoperative hospital stay
timeFrame: from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 1 year
measure: admission to the intensive care unit (ICU)
timeFrame: from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 1 year
measure: adverse events after surgery
timeFrame: from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00148746: Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
Official title: Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Moderate to Severe Atopic Dermatitis
Keywords: atopic dermatitis, atopy
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2005-09-08
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study was designed to test the hypothesis whether a standardized, time-and score-oriented treatment following a strict evidence based algorithm is equally effective to a standard treatment regimen for moderate to severe atopic dermatitis.

Study Type: Mono-centre study, patients are blinded, physicians are randomized to either treat study- or controll group

Eligible are patients age 2 years or older with SCORAD \>= 20 Duration: 12 Months, study visits every 4 weeks.

Primary endpoint is Difference between Baseline SCORAD and mean SCORAD under treatment.

Secundary endpoints are quality of life, safety and economic burden in both treatment groups.


Eligibility criteria: Inclusion Criteria:

* Moderate to severe atopic dermatitis (SCORAD 20 or more) fulfilling the diagnostic criteria by Raika and Hanifin

Exclusion Criteria:

* Pregnancy
* Nursing
* Women in childbearing age without contraception
* Drug - and or alcohol abuse
* Gene defects that are associated with increased light sensibility, e.g. Xeroderma pigmentosum, Cockayne Syndrome, Bloom Syndrome

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: Department of Dermatology, TU Dresden
Study officials:
affiliation: Dpt. of Dermatology, Medical Faculty, Technical University Dresden, Germany
name: Jochen M Schmitt, MD, MPH
role: STUDY_DIRECTOR
References:
citation: Schmitt J, Meurer M, Schwanebeck U, Grahlert X, Schakel K. Treatment following an evidence-based algorithm versus individualised symptom-oriented treatment for atopic eczema. A randomised controlled trial. Dermatology. 2008;217(4):299-308. doi: 10.1159/000151355. Epub 2008 Aug 15.
Clinical trial NCT06531746: Effect of Extracorporeal Shock Wave on Electrophysiological Changes and Pain in Patients With Lower Cross Syndrome
Official title: Effect of Extracorporeal Shock Wave on Electrophysiological Changes and Pain in Patients With Lower Cross Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lower Cross Syndrome
Keywords: Extracorporeal Shock Wave
Electrophysiological changes
Pain
Lower Cross Syndrome
Lead sponsor: AlRyada University for Science & Technology
Sponsor class: OTHER
First posted: 2024-08-01
Enrollment: 44
Sex: ALL
Minimum age (years): 30
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Lower Cross Syndrome happens when there is muscular imbalance between weak and tight muscles. The tight muscles are generally the hip flexors and erector spinae, and weak muscles are the abdominals and gluteal muscles. Shortening occurs in the hip flexors while weakening occurs in the abdominals and gluteal muscles.

Detailed description: Group I (Study): will consist of 22 patients with lower cross syndrome and will receive extracorporeal shock wave in addition to selected physical therapy program. For 12 sessions every other day, each session for 1 hour.

Group II (Control): will consist of 22 patients with lower cross syndrome and will receive selected physical therapy program only same as group (I). For 12 sessions every other day, each session for 1 hour.

Eligibility criteria: Inclusion Criteria:

1. Forty-four lower cross syndrome patients from both genders their ages ranged from 30-45 years old.
2. All patients in present study will be ambulant independently.
3. All patients will be medically stable.
4. The body mass index (BMI) will be ranged from 20:25 Kg/m2.

Exclusion Criteria:

1. Patients with musculoskeletal deformities and disorders.
2. Patients with psychiatric disorders or seizures.
3. Patients with visual and auditory impairment or tremors influencing balance.
4. Patients with other neuromuscular disorders.
5. Patients with BMI more than 25 kg/m2.
6. Patients with cognitive impairment.
7. Patients with lower limb or head and brain surgeries.

Primary outcomes:
measure: Visual Analog Scale
timeFrame: 4 weeks
measure: Electromyograph
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Sadat
country: Egypt
facility: Al Ryada University for Science and Technology
state: Menoufia
Study officials:
References:
Clinical trial NCT01578746: Comparison Between Anterior and Direct Lateral Approach in Total Hip Arthroplasty
Official title: Comparison Between Minimally Invasive Anterior Approach and Direct Lateral Approach in Total Hip Arthroplasty - A Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Coxarthrosis
Keywords: Coxarthrosis
Hip arthroplasty
Anterior approach
Direct lateral approach
Hardinge approach
Smith-Petersen approach
Osteoarthrosis
Lead sponsor: Sorlandet Hospital HF
Sponsor class: OTHER_GOV
First posted: 2012-04-17
Enrollment: 120
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In total hip arthroplasty several approaches can be used. The newly introduced minimally invasive anterior approach is supposed to cause less damage to tendons and muscles. At the same time there are reports that there are more complications when this approach is used. The direct lateral approach is the most used in Norway and is well documented. There are however those who postulate that there is to high risk of damage to the gluteus medius causing Trendelenburg gait. In the investigators hospital both the anterior and direct lateral approach is used with good result. The investigators main study hypothesis is that there is no difference between the use of anterior or direct lateral approach i total hip arthroplasty in regards to postoperative function and pain, complications, radiological finds (X-ray and MRI), markers for muscle damage (i.e CK-total) or other clinical outcomes.


Eligibility criteria: Inclusion Criteria:

* Clinical and radiological diagnosis of coxarthrosis

Exclusion Criteria:

* Previous surgery on affected hip
* No mental disability preventing follow-up

Primary outcomes:
measure: Change in function
timeFrame: 2 years
Secondary outcomes:
measure: Muscle damage
timeFrame: Day of operation and next four consecutive days
measure: Pain
timeFrame: First four postoperative days
measure: X-ray assessment
timeFrame: 3 and 12 months
measure: MRI
timeFrame: 3 and 12 months
Other outcomes:
Locations:
city: Arendal
country: Norway
facility: Sorlandet Hospital HF
Study officials:
affiliation: Sorlandet Hospital HF
name: Svein Andreas Svenningsen, M.D, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06180369: Clinical Efficacies of Different Agents in Molar-Incisor Hypomineralization
Official title: Evaluation of Clinical Efficacies of Different Agents in Molar-Incisor Hypomineralization-Affected Molars
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Molar-Incisor Hypomineralization
Lead sponsor: Marmara University
Sponsor class: OTHER
First posted: 2023-12-22
Enrollment: 120
Sex: ALL
Minimum age (years): 8
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to assess the clinical effectiveness of GC Fuji Triage ® (GC America Inc., Alsip, Illinois) and BeutiSealant (Shofu, Kyoto, Japan) in children aged 8-13 with multiple molars affected by Molar-Incisor Hypomineralization (MIH). The comparison focuses on permanent first molars affected by MIH.

Detailed description: The study targets children within the specified age range with MIH-affected molars, comparing the clinical outcomes of GC Fuji Triage and BeutiSealant. The assessment will provide valuable insights into the efficacy of these agents in managing severe hypomineralization, contributing to our understanding of effective treatment modalities for MIH.

The evaluation criteria include restoration success, prevention of further decay development, prevention of post-eruption breakdown, alleviation of tooth sensitivity, and measurement of life quality. These criteria will be compared with those of Resin Fissure Sealant.

Eligibility criteria: Inclusion Criteria:

* Healthy children aged 8-13 with hypomineralization in their first permanent molars.
* Children without systemic diseases or developmental dental anomalies that could affect hypomineralization.
* Those with at least two molars exhibiting molar-incisor hypomineralization (MIH), specifically scoring 1 and 3 according to the MIH-Tll index.
* Children with a positive or 'definitely positive' cooperation according to the Frankl Behavior Rating Scale (Frankl et al., 1962).
* Absence of spontaneous pain, abscess, mobility, or inter-radicular lesions in the tooth to be treated.
* Patients or their parents consenting to participate in the treatment.

Exclusion Criteria:

* Children with systemic diseases or developmental dental anomalies that could affect hypomineralization.
* To have MIH outside the specified scores.
* Children unable to continue treatment in the chair due to cooperation problems.
* Failure to attend control sessions or a desire not to continue with the study.
* Patients and their parents unwilling to participate in the treatment.
* If the patient cannot attend control sessions or disrupts sessions, they will be withdrawn from the study.

Primary outcomes:
measure: The Schiff Cold Air Sensitivity Score
timeFrame: 1.5 -2 year
measure: Parent Satisfaction
timeFrame: 1.5-2 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01060969: Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention
Official title: Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pulmonary Edema
Cerebral Edema
Keywords: Acute Mountain Sickness
travellers
Acetazolamide
Tadalafil
Acute Mountain Sickness assessed by Lake Louise score
High altitude pulmonary edema
High altitude cerebral edema
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-02-02
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To evaluate the additive value of tadalafil given together with Diamox (acetazolamide) in preventing acute mountain sickness in travelers to high altitude areas.

Detailed description: A randomized controlled study comparing:

Tadalafil \[20mg x1/day\] and acetazolamide \[125mg x2 day\], versus Acetazolamide \[125mg x2 day\] alone, in trekkers to altitude \> 3,000 m.

Eligibility criteria: Inclusion Criteria:

* Participant in trekking to high altitude
* Agreement to sign the informed consent.

Exclusion Criteria:

* No agreement to sign informed consent.

Primary outcomes:
measure: Results will be evaluated by using the Lake Louise AMS scoring system
timeFrame: one month after travel
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Hashomer
country: Israel
facility: Center of Geographic Medicine
city: Tel hashomer
country: Israel
facility: Sheba Medical Ctr.
city: Tel Hashomer
country: Israel
Study officials:
References:
citation: Leshem E, Caine Y, Rosenberg E, Maaravi Y, Hermesh H, Schwartz E. Tadalafil and acetazolamide versus acetazolamide for the prevention of severe high-altitude illness. J Travel Med. 2012 Sep-Oct;19(5):308-10. doi: 10.1111/j.1708-8305.2012.00636.x. Epub 2012 Jul 30.
Clinical trial NCT00816569: Orthokeratology for Keratoconus
Official title: Orthokeratology Contact Lenses for Keratoconus
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Orthokeratology
Keratoconus
Keywords: Orthokeratology
Keratoconus
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2009-01-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To investigate a possible benefit of Orthokeratology contact lenses to improve uncorrected visual acuity of keratoconus patients


Eligibility criteria: Inclusion Criteria:

* Moderate Keratoconus
* No apical scars

Exclusion Criteria:

* Advanced Keratoconus
* Apical scaring
* Contact lens intolerance

Primary outcomes:
measure: Uncorrected Visual acuity
timeFrame: After 1 month
Secondary outcomes:
measure: Amount of change in corneal video-topography
timeFrame: At one month
Other outcomes:
Locations:
city: Jerusalem,
country: Israel
facility: : Hadassah Medical Organization,
Study officials:
References:
Clinical trial NCT04555369: The Value of ctDNA on Chemotherapy Efficacy for mCRC
Official title: Study on the Efficacy of Chemotherapy for Metastatic Colorectal Cancer Evaluated by Circulating Tumor DNA
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Circulating Tumor DNA
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2020-09-18
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The study is designed to evaluate the value of ctDNA in predicting the drug efficacy of chemotherapy for metastatic colorectal cancer.


Eligibility criteria: Inclusion Criteria:

aged ≥18 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma Eastern Cooperative Oncology Group performance status of 0 to 2 life expectancy of ≥ 3 months at least one measurable metastatic lesion have adequate bone marrow, hepatic, and renal function

Exclusion Criteria:

patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction patients with symptomatic brain metastases active clinical severe infection

Primary outcomes:
measure: Response rate
timeFrame: 2 months
Secondary outcomes:
measure: Progression free survival
timeFrame: 2 months
measure: Overall survival
timeFrame: 2 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
References:
Clinical trial NCT00286169: Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
Official title: Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Small-cell Lung Cancer
Keywords: Extensive-disease small-cell lung cancer (ED-SCLC)
Lead sponsor: Sumitomo Pharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2006-02-03
Enrollment: 130
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.


Eligibility criteria: Inclusion Criteria:

* Extensive-disease small-cell lung cancer
* Aged 70 years or older
* Performance status of 0-2
* No prior chemotherapy

Exclusion Criteria:

* Prior therapy for primary lesion
* Pneumonitis and/or pulmonary fibrosis
* Active concomitant malignancy

Primary outcomes:
measure: Overall survival
Secondary outcomes:
measure: Time to progression
measure: Objective tumor response
measure: Quality of Life (QOL: EuroQOL, FACT-L-LCS)
measure: Frequency and severity of adverse events
Other outcomes:
Locations:
city: Chubu
country: Japan
facility: Chubu Region Site
city: Chugoku
country: Japan
facility: Chugoku Region Site
city: Hokkaido
country: Japan
facility: Hokkaido Region Site
city: Kanto
country: Japan
facility: Kanto Region Site
city: Kinki
country: Japan
facility: Kinki Region Site
city: Kyushu
country: Japan
facility: Kyushu Region Site
city: Shikoku
country: Japan
facility: Shikoku Region Site
city: Tohoku
country: Japan
facility: Tohoku Region Site
Study officials:
affiliation: Sumitomo Pharma Co., Ltd.
name: Drug Development Division
role: STUDY_DIRECTOR
References:
Clinical trial NCT05387369: A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
Official title: A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: COVID-19
Keywords: paxlovid
Lead sponsor: Huashan Hospital
Sponsor class: OTHER
First posted: 2022-05-24
Enrollment: 2000
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with COVID-19 who were admitted to Huashan Hospital, Fudan University from 2022 to 2027

Brief summary: The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.

Detailed description: The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collected in this study. The medical data including patient demographic, clinical characteristics, laboratory examination, history of treatments, adverse reactions and treatment outcome will be extracted to analyze the effectivity and safety of paxlovid and explore the prognosis-relevant factors of COVID-19.

Eligibility criteria: Inclusion Criteria:

* Participants who have a positive SARS-CoV-2 test result;
* Participants who have one or more mild or moderate COVID-19 symptoms.

Exclusion Criteria:

* No specific exclusion criteria in this real world study.

Primary outcomes:
measure: Viral shedding time
timeFrame: up to 28 days
measure: Percentage of the participants who have progression of COVID-19
timeFrame: up to 28 days
Secondary outcomes:
measure: AEs and SAEs through Day 28
timeFrame: up to 28 days
measure: Percentage of participants who turned negative for SARS-CoV-2
timeFrame: up to 28 days
measure: Time to sustained clinical recovery
timeFrame: up to 28 days
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Huashan Hospital Affiliated to Fudan University
Study officials:
affiliation: Huashan Hospital affliatied to Fudan University
name: Feng Sun, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01636869: Plasma Concentrations of Bupivacaine After Peri-articular Injection in Total Knee Arthroplasty
Official title: Plasma Concentrations of Bupivacaine After Spinal Anesthesia With Single Shot Femoral Nerve Block and Peri-articular Injection in Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Serum Bupivacaine Level
Periarticular Block
Total Knee Arthroplasty
Keywords: bupivacaine level
periarticular block
total knee arthroplasty
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2012-07-10
Enrollment: 43
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Patients with knee arthroplasty usually performed under spinal anesthesia with a single-shot femoral nerve block and periarticular block, so we would like to know the plasma concentration of bupivacaine in these patients.


Eligibility criteria: Inclusion Criteria:

* age of 30-70 yr
* ASA I-II
* patient undergo total knee arthroplasty under spinal block and single shot femoral nerve block and periarticular block

Exclusion Criteria:

* patient's refusal
* allergic to bupivacaine
* body weight less than 50 kg
* liver disease
* heart disease
* coagulopathy
* Hct\<35%
* infection at both groin

Primary outcomes:
measure: plasma concentration of bupivacaine after spinal anesthesia with single-shot femoral nerve block and periarticular block
timeFrame: 2 hours
Secondary outcomes:
measure: bupivacaine toxicity
timeFrame: 24 hr
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Faculty of Medicine, Siriraj Hospital, Mahidol University
Study officials:
References: